Antioxidant and Hepatoprotective Activity of a New Tablets Formulation from Tamarindus indica L.
Table 1
Corporal weight gain and relation between rat liver and final corporal weight (standard deviation on parenthesis).
Group
Initial body weight (g)
Final body weight (g)
Body weight gain (g)
Liver weight (g)
Liver weight/final body weight (%)
I
176.39 (12.23)
212.23 (13.42)
35.84 (3.25)
3.49 (0.80)
1.64 (0.22)
II
189.24 (13.88)
194.70 (17.40)
5.46 (1.99)
4.85 (0.86)
2.49 (0.51)
III
175.29 (12.26)
214.87 (25.21)
39.58 (4.52)
3.41 (0.75)
1.59 (0.29)
IV
181.36 (12.54)
223.47 (13.15)
42.11 (4.12)
3.86 (0.65)
1.72 (0.35)
V
191.86 (13.47)
229.93 (16.69)
38.07 (3.57)
3.75 (0.92)
1.63 (0.26)
I: control group; II: CCl4 induced hepatotoxicity group; III: Silymarin treated group; IV and V: Tamarindus indica L. tablets treated groups at doses 100 mg/kg and 200 mg/kg, respectively. Different letters on columns indicate significant statistical differences ().
